Evercore ISI Reiterates $70 PT on Intellia Therapeutics (NTLA), 'Year of P3 execution'
Tweet Send to a Friend
Evercore ISI analyst Liisa Bayko reiterated an Outperform rating and $70.00 price target on Intellia Therapeutics (NASDAQ: NTLA).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
